Key result
SAPT after LAAC is linked to fewer hemorrhagic events without increasing embolic risk.
Why the study?
The optimal post-procedural antithrombotic regimen following percutaneous left atrial appendage closure remains controversial.
Does single antiplatelet therapy reduce hemorrhagic events without increasing embolic events compared to other antithrombotic regimens in patients after left atrial appendage closure?
Population
140 patients who underwent LAA closure at a single center
Comparison
SAPT vs DAPT vs OAC vs combined OAC and antiplatelet therapy
Design
Single-center retrospective cohort study
Follow-up
Mean 24.3 ± 14.7 months
Authors
Loading...
May favor SAPT post-LAA closure to reduce bleeding without embolic trade-off; leaves open randomized confirmation before practice change.
Cohort (n=140)
No
Does single antiplatelet therapy reduce hemorrhagic events without increasing embolic events compared to other antithrombotic regimens in patients after left atrial appendage closure?
p-value: p=0.133 for embolic events; 0.0015 for hemorrhagic events
Single antiplatelet therapy after LAA closure appears to offer a safer bleeding profile without compromising embolic protection compared to more intensive antithrombotic regimens.
Alonso et al. (2025) conducted a cohort in Non-valvular atrial fibrillation with contraindications to long-term oral anticoagulation (n=140). Single antiplatelet therapy (SAPT) vs. Other antithrombotic regimens (DAPT, OAC, combined OAC and antiplatelet) was evaluated on Embolic and hemorrhagic events (p=0.133 for embolic events; 0.0015 for hemorrhagic events). Single antiplatelet therapy after left atrial appendage closure was associated with a significantly lower risk of hemorrhagic events (p=0.0015) without increasing embolic events (p=0.133).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: